Study Shows Improved Survival In Aggressive Acute Myeloid Leukemia
Patients who relapse in their battle with acute myeloid leukemia (AML)
may benefit from a phase three study of therapies that combine an
existing agent, cytarabine, with a newer compound, vosaroxin.
Source: M. D. Anderson Cancer Center - News Releases - Category: Cancer & Oncology Source Type: news